Editas Medicine (EDIT) News Today $1.35 +0.03 (+2.27%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.03 (-2.22%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period GC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh GolipourApril 15 at 7:31 PM | finance.yahoo.com238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 238,967 shares of the company's stock, valued at approximately $303,00April 12 at 3:08 AM | marketbeat.comBroad, Harvard researchers win Breakthrough Prize, known as 'Oscars of Science'April 6, 2025 | bizjournals.comEditas Medicine: Do The Risks Outweigh The Rewards?April 3, 2025 | seekingalpha.comZacks Research Raises Earnings Estimates for Editas MedicineEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 earnings estimates for Editas Medicine in a research note issued on Wednesday, March 26th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($March 31, 2025 | marketbeat.comZacks Research Comments on Editas Medicine FY2027 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Editas Medicine in a note issued to investors on Wednesday, March 26th. Zacks Research analyst A. Chakraborty expects that the company will post earnMarch 29, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Share Price Passes Below 50 Day Moving Average - Here's WhyEditas Medicine (NASDAQ:EDIT) Stock Price Passes Below 50-Day Moving Average - Time to Sell?March 26, 2025 | marketbeat.comEditas Medicine appoints new CFO as Lucera steps downMarch 22, 2025 | investing.comEditas Medicine appoints new CFO amid executive reshuffleMarch 22, 2025 | investing.comEditas Medicine CFO Erick Lucera to step down, Amy Parison to succeedMarch 21, 2025 | markets.businessinsider.comDyne Therapeutics Names Editas Medicine's Lucera as CFOMarch 21, 2025 | marketwatch.comEditas Medicine Announces Chief Financial Officer TransitionMarch 20, 2025 | globenewswire.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Large Decrease in Short InterestEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 13,770,000 shares, a decline of 21.0% from the February 13th total of 17,440,000 shares. Currently, 17.0% of the company's stock are short sold. Based on an average daily volume of 4,140,000 shares, the days-to-cover ratio is currently 3.3 days.March 18, 2025 | marketbeat.comMonaco Asset Management SAM Buys Shares of 1,069,732 Editas Medicine, Inc. (NASDAQ:EDIT)Monaco Asset Management SAM bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,069,732 shares ofMarch 15, 2025 | marketbeat.comHere's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash WiselyMarch 13, 2025 | uk.finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by AnalystsEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been assigned an average rating of "Hold" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and threeMarch 12, 2025 | marketbeat.comEditas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)March 11, 2025 | seekingalpha.comEditas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business UpdatesMarch 7, 2025 | finanznachrichten.deEditas Medicine (EDIT) Gets a Buy from Evercore ISIMarch 7, 2025 | markets.businessinsider.comEditas Medicine (NASDAQ:EDIT) Announces Earnings ResultsEditas Medicine (NASDAQ:EDIT - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%.March 6, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings ResultsEditas Medicine (NASDAQ:EDIT - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%.March 6, 2025 | marketbeat.comBarclays Keeps Their Hold Rating on Editas Medicine (EDIT)March 6, 2025 | markets.businessinsider.comEditas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business UpdatesMarch 5, 2025 | globenewswire.comEditas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference TranscriptMarch 3, 2025 | seekingalpha.comEditas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in MarchFebruary 24, 2025 | globenewswire.comEditas Medicine (EDIT) to Release Earnings on WednesdayEditas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, February 26.February 24, 2025 | marketbeat.comEditas Medicine (EDIT) Expected to Announce Earnings on WednesdayEditas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by BrokeragesEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received an average recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommeFebruary 15, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Stock Passes Below 200-Day Moving Average - Here's What HappenedEditas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Two Hundred Day Moving Average - Here's WhyFebruary 13, 2025 | marketbeat.comEditas Medicine stock hits 52-week low at $1.12 amid downturnFebruary 11, 2025 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Significant Growth in Short InterestEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 18,210,000 shares, an increase of 7.6% from the December 31st total of 16,930,000 shares. Based on an average daily volume of 2,620,000 shares, the short-interest ratio is currently 7.0 days.February 4, 2025 | marketbeat.comChardan Capital downgrades CARGO Therapeutics, Inc. (CRGX) to a HoldJanuary 31, 2025 | markets.businessinsider.comLeerink Partnrs Weighs in on Editas Medicine FY2025 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Editas Medicine in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the companJanuary 24, 2025 | marketbeat.comFY2024 EPS Estimates for Editas Medicine Lowered by AnalystEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities researchers at Zacks Research dropped their FY2024 EPS estimates for Editas Medicine in a note issued to investors on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per shareJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Estimates Editas Medicine FY2025 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Editas Medicine in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earninJanuary 23, 2025 | marketbeat.comBrokers Offer Predictions for Editas Medicine FY2025 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Editas Medicine in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($2.1January 22, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest UpdateEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 18,210,000 shares, a growth of 7.6% from the December 15th total of 16,930,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the short-interest ratio is currently 7.0 days.January 19, 2025 | marketbeat.comBank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)January 16, 2025 | markets.businessinsider.comEditas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)January 15, 2025 | seekingalpha.comEditas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing AdvancementsJanuary 15, 2025 | markets.businessinsider.comEditas Medicine (EDIT) Receives a Buy from TD CowenJanuary 14, 2025 | markets.businessinsider.comEditas Medicine announces strategic priorities, 2025 key milestonesJanuary 13, 2025 | markets.businessinsider.comEditas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesJanuary 13, 2025 | globenewswire.comIntellia Therapeutics (NTLA) Receives a Buy from Evercore ISIJanuary 10, 2025 | markets.businessinsider.comGene editing stocks drop as Intellia announces layoffsJanuary 10, 2025 | msn.comEditas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Rises By 5.4%Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 16,930,000 shares, a growth of 5.4% from the November 30th total of 16,060,000 shares. Based on an average daily volume of 2,450,000 shares, the short-interest ratio is presently 6.9 days.January 1, 2025 | marketbeat.comSangamo Biosciences: Hold Rating Amidst Funding Challenges and Strategic UncertaintyDecember 31, 2024 | markets.businessinsider.comWhy Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by State Street CorpState Street Corp reduced its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,462,022 shares of the company's stock after seDecember 28, 2024 | marketbeat.com Remove Ads Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼1.290.78▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼34▲EDIT Articles Average Week Remove Ads Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maze Therapeutics News Today Kamada News Today Checkpoint Therapeutics News Today Ginkgo Bioworks News Today Rapport Therapeutics News Today Autolus Therapeutics News Today Alumis News Today Sana Biotechnology News Today Stoke Therapeutics News Today Tourmaline Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts